Locoregional MYCN-amplified neuroblastoma

Pediatr Blood Cancer. 2012 Oct;59(4):736-8. doi: 10.1002/pbc.24003. Epub 2012 Jan 1.


MYCN-amplification is strongly associated with other high-risk prognostic factors and poor outcome in neuroblastoma. Infrequently, amplification of MYCN has been identified in localized tumors with favorable biologic features. Outcome for these children is difficult to predict and optimal treatment strategies remain unclear. We report a 5-month-old who presented with an MYCN-amplified INSS stage 3, pelvic neuroblastoma. The tumor had favorable histology, hyperdiploidy, and lacked 1p36 and 11q23 aberrations. Although the patient met the criteria for high-risk neuroblastoma, because of the discordant prognostic markers we elected to treat her according to an intermediate-risk protocol. She remains event-free more than 18 months.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Gene Amplification*
  • Humans
  • Infant
  • N-Myc Proto-Oncogene Protein
  • Neuroblastoma / genetics*
  • Neuroblastoma / pathology
  • Neuroblastoma / surgery
  • Nuclear Proteins / genetics*
  • Oncogene Proteins / genetics*
  • Pelvic Neoplasms / genetics*
  • Pelvic Neoplasms / pathology
  • Pelvic Neoplasms / surgery
  • Prognosis


  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Nuclear Proteins
  • Oncogene Proteins